ATLAS meta-analysis of 6 trials on EVT for large core infarcts confirms large treatment effect of EVT, reducing disability and mortality, with a NNT of 4,2. Treatment benefit was consistent over clinical and most imaging subgroups. @ESOstroke #VoiceOfStroke #Stroke #ESOC2026

Presenting at #ESOC2026, the ATLAS study found endovascular thrombectomy was associated with improved functional outcomes & reduced mortality vs medical management in patients with large-core ischaemic stroke presenting within 24h of onset. spkl.io/6016A7GFg @ESOstroke

On behalf of the large core trials principal investigators, immensely proud and honored to present primary results of the ATLAS IPD meta-analysis @ESOstroke with simultaneous publication in @TheLancet -thelancet.com/journals/lance… EVT not only improved outcomes compared to medical care, but functional independence and independent ambulation were also achieved in a meaningful proportion of patients. Additionally, EVT was life-saving, as one of the few reperfusion therapies to achieve it. With the exception of patients with very large core (volume ≥150 ml) in the late time window, where evidence is limited because of wide confidence intervals but benefit could not be excluded, EVT demonstrated consistent benefit regardless of ASPECTS and ischaemic core strata. Our deepest gratitude to the patients, their families, and all investigators and coordinators at the trial sites. A mammoth collective effort over 3 years from 6 trials with practice changing results that improve care for 20% LVOs! #stroke #EVT #largecore #NoLVOleftbehind @XiaochuanHuo @VCostalat @oozaidat @VYogendrakumar @deeppujara @dliebesk @ARazzakMD @NguyenThanhMD @samialkasab @AmeerEHassan @Michael3Abraham @FelixSun1230 @HiroshiYamagam2 @SunilAShethMD @Fie0815 @RaulNogueiraMD @rgrandhi @PascalJabbourMD @shazamhussain @dr_mchen @mihill68 @lapergue6 @TudorGJovin @AlbertJYoo

Women Benefit Equally From Endovascular Thrombectomy for Large Core Ischemic Stroke in a Subanalysis of SELECT2 In this #BloggingStroke post, @drchloemutimer discusses #Stroke article by @JPTsaiMD et al. #AHAJournals #GoRedForWomen ahajournals.org/do/10.1161/b…

Congratulations to @JPTsaiMD on leading the analysis on sex-based differences in EVT outcomes for large strokes from @SELECT2Trial, published in @StrokeAHA_ASA's #GoRedforWomen collection. No significant heterogeneity in EVT benefits across sexes. Age and ischemic core size remained prognostic in both males and females.@NguyenThanhMD @deeppujara @johannatfifi @Michael3Abraham @dr_mchen @shazamhussain @CerebrovascLab @aopaskar @marcriboj @AmeerEHassan @StavTjoumakaris @mihill68 @natperezossa @anjailibrahim @fournier_lauren @NeuroFaris

.@UHhospitals has been awarded US$7 million in research funding by @PCORI to evaluate endovascular #Thrombectomy in patients presenting more than 24 hours from time last known well via the global SELECT LATE clinical trial @amrsarrajMD @SELECT2Trial neuronewsinternational.com/s…

Honored and grateful for the opportunity to assess the role of Endovascular Thrombectomy beyond 24 hours of last known well through SELECT LATE international, multicenter pragmatic clinical trial - pcori.org/research-results/2… funded by @PCORI @UHhospitals Excited to collaborate with my Co-Investigators Bruce Campbell @UniMelb, Jeff Saver @UCLANeurology, Jim Grotta @memorialhermann, @NguyenThanhMD @The_BMC, @StavTjoumakaris @TJUHNeurosurg, Steve Messe @PennNeurology, Leonid Churilov @UniMelb and Clark Sitton @McGovernMed for the successful conduct of the trial. Grateful to our stakeholders @MitchElkind, @AmeerEHassan, @dr_mchen, Erin Supan, Eric Hess, Daniel Ellenberger and patients’ advocates Christina Globuski, Matthew and Laura Antenucci, James and Jessica Sulecki and Kelly Montgomery for their guidance on how to make our study more pragmatic and patient-centered.

Congratulations @AmeerEHassan @Michael3Abraham on leading analyses on effect of procedure characteristics and reperfusion success on EVT outcomes for patients with large strokes from @SELECT2Trial onlinelibrary.wiley.com/doi/… @ANA_journals ~80% procedural success that improved clinical outcomes and reduced infarct growth. eTICI 2c-3 improved outcomes compared to those with eTICI 2b. Prolonged procedures were associated with worse outcomes. Consistent results across aspiration first vs stent retriever approaches. @shazamhussain, @CerebrovascLab, @dr_mchen, @deeppujara, @NabeelHerial, @JPTsaiMD, @DrPatchiz, @drricardohanel, @almuftifawaz, @AndrewKCheung, @jordiblascoa, @LUISANROMA, @NiravAVora, @DanSahlein, @LElijovich, @ArenillasJF, @Teddyyhwu, @PCardonaP, @natperezossa, @JoannaSchaafsma, @BJHicksMD, @NaviSSangha, @warach_steven, @TimothyKleinig, @Faris_Shaker, @FreqFrequentist, @wondeasa, @mark_dannenbaum, @GaborTothMD, @AmuluruKrishna, @JanKarlBurkhar1, @ARazzakMD,  @HarisKamalMD, @vitorpereiracan, @NguyenThanhMD, @Johannatfifi, @esamaniego, @AdamArthurMD, @StavTjoumakaris, @PascalJabbourMD, @jimgrotta, @mihill68, @marcriboj

Our comprehensive review @ANA_journals on current neuroimaging evidence for reperfusion therapies, shifting treatment paradigms and utility of different imaging modalities in acute ischemic stroke. @DrBruceCampbell @deeppujara onlinelibrary.wiley.com/doi/…

Honored to receive the 2024 Clinical Research Forum top 10 award on behalf of @SELECT2Trial investigators.Inspiring & motivational to see exciting progress on many healthcare fronts by elite clinician scientists.This recognition motivates us to keep pushing boundaries @CRForumUS

🎯 Major Findings in Stroke 🌟 Hopeful twist in recovery! Despite 75% patients experience intracranial hemorrhage post-EVT, functional outcomes remain unaffected. 🧠💪 SELECT2 trial shows hemorrhages are not the end of the road! 🚀 Read the full study 👉 bit.ly/3xf5tfu

Proud and honored to present @SELECT2Trial results at #ISC2023 EVT is safe and efficacious in large core! We’re a step closer to improving more patients lives. nejm.org/doi/full/10.1056/NE…

Our latest @JAMANeuro “SELECT Late” international cohort study; EVT was associated with increased odds of functional independence in selected patients treated beyond 24 hours of last known well #NoLVOleftbehind #stroke #neurology jamanetwork.com/journals/jam…

We’ve made it to 800 followers. Be apart if the conversation by sharing and commenting on ACTN and Annals of Neurology publications on Twitter. Help us make it to 1000 followers. Tag a friend who shouldn’t miss out! @TheNewANA1 @AANmember.

Hello #NeuroTwitter Join us in welcoming our awesome residency program director, @DCPneuro to the world of #Twitter 🥳 It took a long time convincing him, so show him some love 🧠❤️ #NeurologyProud @AANEMorg @AANMember #Neurology #Residency @NMatch2023

I sit with the legendary @jimgrotta to discuss #BEST-MSU. MSU 🚑 provides faster thrombolysis, enhances #stroke outcomes, shortens time to EVT and is cost-effective. This world renowned strokologist, and my mentor, is a great listen. Like an old wine, only gets better with age!

sciencedirect.com/science/ar… Our #latest meta-analysis review on direct carotid access when it is absolutely necessary to go north & giving up is not an option!#GTFVO #NeverBackDown @visishs @almuftifawaz @KunalVakhariaMD @amrsarrajMD @svinsociety @AmeerEHassan @elghanemmoh

Latest content - bit.ly/3KjDwVa - Fifi et al. found women had similar discharge outcomes as men following #EVT, but the improvement from discharge to 90 days was significantly worse in women. @johannatfifi @Faris_Shaker @amrsarrajMD @StavTjoumakaris @AnneAlexandrov

❗Late breaking oral abstracts happening now #ISC22❗ Update on this trial: SELECT2 seeks to evaluate thrombectomy in patients with large core on perfusion imaging 👏 Interim analysis showed no safety concerns and will continue enrollment 👏 @amrsarrajMD

…time & start focusing on salvageable tissue w disabling deficits as primary indication for MT. More data presented today #ISC22 showing benefit of MT >24hrs by @amrsarrajMD. More data coming…@GhadaMohamedMD @aboulnourh @OwaisAlsrouji @HenryFordNeuro @AshuPJadhav @stephanamayer